Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Live Updating

Newer

dorothy52

10/03/17 5:17 PM

Post #6

Re: #5: @jaybe - PE’s are all over the map, I mean

There's about 25 million shares right? So with residual earning of 2 billion and shares priced at 150 that gives us a P/E of a little over 1x

jaybe

10/03/17 2:55 PM

Post #5

Re: #4: @dorothy52 - All green for me as well. 10 bagger?

PE’s are all over the map, I mean PPS.. as in $150 pps in 2022.

dorothy52

10/03/17 2:16 PM

Post #4

Re: #1: @jaybe - MRSN...all green lights for me...

All green for me as well. 10 bagger? I know several biotech trading at a much higher p/e than that. Look at where we are trading now. But all depends on when we start to see approval for drugs to be marketed

jaybe

09/22/17 10:06 PM

Post #3

Mersana picks up 'Best New Drug Developer' at World ADC 2017...

Not a huge pool of candidates here, but in 2016 Mersana was 'Best ADC Platform Technology' and runner-up for 'Best New Drug Developer'.

http://worldadc-awards.com/about/2017-winners/

jaybe

07/21/17 10:19 PM

Post #2

Should see analyst coverage Monday...expiration of quiet period..

JP Morgan, Cowen, Leerink, and/or Wedbush

jaybe

07/16/17 2:36 PM

Post #1

MRSN...all green lights for me...

Award-winning platform, outstanding pre-clinical with proven MOAs and targets, strong team, multi-billion dollar markets for both lead compounds consisting of several potential indications.

Will have 3-4 candidates in clinic by end of 2018, 2 internal and 1-2 with partners (Merck KgaA and/or Takeda). Recent IPO (June) with steady flow of milestones (up to $2B) from partnerships.

Looking at a 5-year 10-bagger here...good luck to all.

Will post often here.

Newer

MERSANA THERAPEUTICS, INC. (MRSN)

Followers	7	Posters	19
Posts (Today)	0	Posts (Total)	56
Created	07/09/17	Type	Free
Moderators

Mersana Therapeutics, Inc. is a biotechnology company that discovers, engineers, and develops antibody drug conjugates to cure various cancers. The company develops immune conjugate therapies to create drugs that enhance patients lives. It offers XMT-1522, a drug therapy for tumor models that express relatively low amounts of the HER2 protein; and human anti-HER2 antibody used in XMT-1522. Mersana Therapeutics, Inc. has strategic alliances with Takeda Pharmaceutical Company Limited; Merck Serono; and Asana BioSciences. The company was formerly known as Nanopharma Corp. and changed its name to Mersana Therapeutics, Inc. in November 2005. Mersana Therapeutics, Inc. was founded in 2001 and is based in Cambridge, Massachusetts.